Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 26, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
October 24, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

BASKING RIDGE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
October 17, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer
September 28, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Participation in Upcoming Conferences in October

BASKING RIDGE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
September 20, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Participation in InfoSec World 2023

BASKING RIDGE, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
September 12, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone in subjects with advanced solid tumors...
September 06, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

BASKING RIDGE, N.J., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
September 05, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces Participation in Upcoming Conferences in September

BASKING RIDGE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...
August 14, 2023 16:05 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Cash runway projected into first quarter 2026 based on capital conservation measures implemented without impact to clinical development pipeline Technology transfer agreement executed for Company’s...
August 08, 2023 08:00 ET | Source: Lisata Therapeutics, Inc.

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies...